Premium
Treatment for children with severe aplastic anemia and sickle cell disease in low income countries in Latin America: A report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO): Part III
Author(s) -
Howard Scott C.,
Wilimas Judy A.,
Flores Andronica,
Pacheco C.,
de Reyes Gladis,
Machin Sergio,
Svarch Eva,
Navarrete Marta,
Nieves Rosa,
Rodriguez Hilze,
Masera Giuseppe
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20988
Subject(s) - medicine , hematology , aplastic anemia , disease , pediatrics , anemia , sickle cell anemia , transplantation , hematopoietic stem cell transplantation , intensive care medicine , bone marrow
Treatment of hematologic disorders in low‐income countries (LIC) is difficult. This report summarizes treatment of sickle cell disease and aplastic anemia by pediatric hematologists from 15 LIC who participate in the Monza International School of Pediatric Hematology/Oncology (MISPHO). Patients with severe sickle cell disease were treated with low dose hydroxyurea, which safely reduced vaso‐occlusive crises. Patients with severe aplastic anemia fared poorly due to lack of availability and high cost of anti‐thymocyte globulin and cyclosporine and lack of access to stem cell transplantation. Appropriate therapy was most likely to occur in MISPHO centers with an active twinning program with a center in a high‐income country. Pediatr Blood Cancer 2007;48:598–599. © 2006 Wiley‐Liss, Inc.